Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health’s CME/NCPD/CPE–approved activity, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). This month, numerous updates in the use of radiotherapy for SCLC were presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting. In this interview, Dr. Park outlines the most significant updates presented at ASTRO and how he plans to incorporate them into the treatment of patients with SCLC. 

At the end of the interview, stay tuned to hear Dr. Park's full presentation and claim credit at https://gate.sc/?url=https%3A%2F%2Fwww.i3health.com%2Fcourse-information%2Fvideo-viewpoint-strategy-session-optimizing-treatment-selection-sequencing-and-tolerability-in-small-cell-lung-cancer&token=7e964b-1-1698857353561

Additional Advances in SCLC Radiotherapy With Henry Park, MD, MPH + Free CME/NCPD/CPE Podcast

Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approved activity, Evolving Treatment Concepts and New Data in Advanced Prostate Cancer. 

Since recording, a plethora of new data and treatment options have been made available for prostate cancer, as well as additional ongoing and future clinical trials to look forward to. In this interview, Dr. Dorff catches us up to speed on these new advancements and shares resources and advice for clinicians working in the field of prostate cancer.

To view or complete the CME activity, click here: https://bit.ly/3uLwVRb

Additional Advances in Advanced Prostate Cancer With Tanya Dorff, MD

At the recent American Society of Hematology (ASH) Annual Meeting, numerous updates were presented with the potential to impact practice in relapsed/refractory multiple myeloma. While at the meeting, Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, shares some of most significant highlights of the clinical trials and therapeutic agents being presented. After listening to the podcast, be sure to watch Dr. Shah's free CME activity or book a live meeting for your institution to hear more expert perspectives on new directions in multiple myeloma treatment!  

Free CME activity: https://www.i3health.com/course-information/expert-guidance-on-current-standards-and-new-directions-in-newly-diagnosed-multiple-myeloma

Book a meeting for your institution: https://www.i3health.com/live/expert-guidance-on-current-standards-and-new-directions-in-newly-diagnosed-multiple-myeloma-1

Highlights of Multiple Myeloma Research Presented at ASH With Urvi Shah, MD

Last year, Jaffer Ajani, MD, Professor in the Department of Gastrointestinal (GI) Medical Oncology at MD Anderson Cancer Center, served as co-chair of i3 Health's Virtual Tumor Board, Building Comprehensive Care Plans in Esophagogastric Cancers, along with Lei Zhao, MD, PhD, Assistant Professor of Pathology at Brigham and Women's Hospital, and Kelly Rone, DNP, RN, AGNP-c, Advanced Practice Nurse at the Mayo Clinic. With numerous developments in the field occurring since recording the activity, Dr. Ajani sat down with Oncology Data Advisor to provide an update on the evolving field of esophagogastric cancer research and advances to look forward to in the coming years.

Click here to view and claim credit for Building Comprehensive Care Plans in Esophagogastric Cancer, an accredited CME/NCPD activity provided by i3 Health: https://www.i3health.com/course-information/virtual-tumor-board-building-comprehensive-care-plans-in-esophagogastric-cancers

Additional Advances in Esophagogastric Cancer Research and Clinical Trials With Jaffer Ajani, MD

Dr. Spero Cataland, Professor of Internal Medicine and the Benign Hematology Section Head at The Ohio State University, Wexner Medical Center, is currently serving as chair of i3 Health's free CME/NCPD activity and Hematology Fellows Lecture Series, Current Standards and New Directions in Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). In this interview, Dr. Cataland provides an update on new research that has occurred in the field during the past year and shares a preview of what learners can look forward to when attending his presentation at their own institution.

Use this link to complete the CME/NCPD activity and claim credit: https://bit.ly/3xxJFvW

Additional Advances in aTTP Research and Clinical Trials With Spero Cataland, MD

Dr. Christopher Lieu, Associate Director of Clinical Research at the University of Colorado Cancer Center and Vice Chair of the National Comprehensive Cancer Network (NCCN), is currently serving as chair of i3 Health's online activity, live webinar, and meeting series, Hitting the Target in HER2-Positive Metastatic Colorectal Cancer. With numerous research advances occurring in this field during the past year, Dr. Lieu sat down with us again to share updates in targeted therapies for HER2-positive metastatic colorectal cancer and the evolving landscape of biomarkers under investigation for this disease.

Click the links below for Hitting the Target in HER2-Positive Metastatic Colorectal Cancer, an accredited CME/NCPD activity provided by i3 Health!

Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/hitting-the-target-in-her2-positive-metastatic-colorectal-cancer

Live Webinar Registration: https://www.i3health.com/course-information/Colorectal-Cancer-Webinar

Live or Virtual Meeting Series: https://www.i3health.com/live/hitting-the-target-in-her2-positive-metastatic-colorectal-cancer-1

Additional Advances in HER2-Positive Metastatic Colorectal Cancer Research: Christopher Lieu, MD

Last year, Brian Rubin, MD, PhD, Chair of Pathology and Laboratory Medicine and the Chief of Diagnostics at the Cleveland Clinic, served as co-chair for i3 Health's continuing medical education CME NCPD #virtualtumorboard: Multidisciplinary Management of Advanced Soft Tissue Sarcoma. 

In this interview, Dr. Rubin sat down with Oncology Data Advisor  to discuss updates in the treatment and management of soft tissue sarcoma, what to look forward for the future of treating sarcomas, and his passion for this field. Watch the interview now and complete the activity here: https://bit.ly/3tHGzni

Additional Advances in Soft Tissue Sarcoma With Brian Rubin, MD, PhD

i3 Health's mission is to enhance the proficiency of the multidisciplinary health care team by providing evidence-based, fair-balanced CME/NCPD/CPE activities that address identified professional practice gaps and unmet educational needs.

Additional Advances in Soft Tissue Sarcoma With Brian Rubin, MD, PhD

i3 Health

Related tracks